# "The Once A Day Protease Inhibitor Regimens"

> **NCT00242216** · PHASE4 · COMPLETED · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 76 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** ritonavir-boosted atazanavir
- **DRUG:** ritonavir-boosted fosamprenavir

## Key facts

- **NCT ID:** NCT00242216
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2014-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242216, ""The Once A Day Protease Inhibitor Regimens"". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00242216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*